Protocol Ledger

NCT05036135 · Phase II/III · TERMINATED

A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Interventional Phase II/III clinical trial protocol NCT05036135 sponsored by Aerovate Therapeutics in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-02 Enrollment: 202 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05036135
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)202 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05036135
Protocol FieldVerified Registry Value
NCT IdentifierNCT05036135
Consolidated Lead SponsorAerovate Therapeutics
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II/III
Overall Recruitment StatusTERMINATED
Registered Enrollment202 participants (ACTUAL)
Registered Start Date2021-12-02
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI